Age-related macular degeneration: Clinical findings, histopathology and imaging techniques

Cell-Based Therapy for Retinal Degenerative Disease

Volumn 53, Issue , 2014, Pages 1-32

  Zarbin, Marco A ^a   Casaroli Marano, Ricardo P ^c   Rosenfeld, Philip J ^b  

^a INSTITUTE OF OPHTHALMOLOGY AND VISUAL SCIENCE   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84925875760     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000358536     Document Type: Chapter

References (207)

1. Chew WC, Clemons TE, Bressler SB, et al: Randomized Trial of a Home Monitoring System for Early Detection of Choroidal Neovascularization Home Monitoring of the Eye (HOME) Study. Ophthalmology DOI: 10.1016/j. ophtha.2013.10.027.
2. Zarbin MA: Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 2004; 122: 598-614.
3. Handa JT: How does the macula protect itself from oxidative stress? Mol Aspects Med 2012; 33: 418-435.
4. Sparrow JR, Ueda K, Zhou J: Complement dysregulation in AMD: RPEBruch's membrane-choroid. Mol Aspects Med 2012; 33: 436-445.
5. Ferris FL, Davis MD, Clemons TE, et al: A simplified severity scale for age-related macular degeneration: AREDS Report No. 18. Arch Ophthalmol 2005; 123: 1570-1574.
6. Wang JJ, Foran S, Smith W, Mitchell P: Risk of age-related macular degeneration in eyes with macular drusen or hyperpigmentation: the Blue Mountains Eye Study cohort. Arch Ophthalmol 2003; 121: 658-663.
7. Klein R, Klein BE, Tomany SC, Meuer SM, Huang GH: Ten-year incidence and progression of age-related maculopathy: The Beaver Dam eye study. Ophthalmology 2002; 109: 1767-1779.
8. van Leeuwen R, Klaver CC, Vingerling JR, Hofman A, de Jong PT: The risk and natural course of age-related maculopathy: follow-up at 6 1/2 years in the Rotterdam study. Arch Ophthalmol 2003; 121: 519-526.
9. The Age-Related Eye Disease Study system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the Age-Related Eye Disease Study Report Number 6. Am J Ophthalmol 2001; 132: 668-681.
10. Jain N, Farsiu S, Khanifar AA, et al: Quantitative comparison of drusen segmented on SD-OCT versus drusen delineated on color fundus photographs. Invest Ophthalmol Vis Sci 2010; 51: 4875-4883.
11. Leuschen JN, Schuman SG, Winter KP, et al: Spectral-domain optical coherence tomography characteristics of intermediate age-related macular degeneration. Ophthalmology 2013; 120: 140-150.
12. Folgar FA, Chow JH, Farsiu S, et al: Spatial correlation between hyperpigmentary changes on color fundus photography and hyperreflective foci on SDOCT in intermediate AMD. Invest Ophthalmol Vis Sci 2012; 53: 4626-4633.
13. Hawkins BS, Bird A, Klein R, West SK: Epidemiology of age-related macular degeneration. Mol Vis 1999; 5:26.
14. Vingerling JR, Klaver CC, Hofman A, de Jong PT: Epidemiology of age-related maculopathy. Epidemiol Rev 1995; 17: 347-360.
15. Friedman DS, O'Colmain BJ, Munoz B, et al: Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004; 122: 564-572.
16. Prokofyeva E, Zrenner E: Epidemiology of major eye diseases leading to blindness in Europe: a literature review. Ophthalmic Res 2012; 47: 171-188.
17. Owen CG, Jarrar Z, Wormald R, Cook DG, Fletcher AE, Rudnicka AR: The estimated prevalence and incidence of late stage age related macular degeneration in the UK. Br J Ophthalmol 2012; 96: 752-756.
18. Rudnicka AR, Jarrar Z, Wormald R, Cook DG, Fletcher A, Owen CG: Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis. Ophthalmology 2012; 119: 571-580.
19. Spanish Epidemiological Eye Study (SEES): Prevalence of age-related macular degeneration in Spain. Br J Ophthalmol 2011; 95: 931-936.
20. Furtado JM, Lansingh VC, Carter MJ, et al: Causes of blindness and visual impairment in Latin America. Surv Ophthalmol 2012; 57: 149-177.
21. Smith W, Assink J, Klein R, et al: Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology 2001; 108: 697-704.
22. Kawasaki R, Yasuda M, Song SJ, et al: The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis. Ophthalmology 2010; 117: 921-927.
23. Friedman DS, Katz J, Bressler NM, Rahmani B, Tielsch JM: Racial differences in the prevalence of age-related macular degeneration: the Baltimore Eye Survey. Ophthalmology 1999; 106: 1049-1055.
24. Klein R, Klein BE, Knudtson MD, Meuer SM, Swift M, Gangnon RE: Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology 2007; 114: 253-262.
25. Klaver CC, Assink JJ, van Leeuwen R, et al: Incidence and progression rates of age-related maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci 2001; 42: 2237-2241.
26. Choudhury F, Varma R, McKean-Cowdin R, Klein R, Azen SP: Risk factors for four-year incidence and progression of age-related macular degeneration: the Los Angeles Latino Eye Study. Am J Ophthalmol 2011; 152: 385-395.
27. Yasuda M, Kiyohara Y, Hata Y, et al: Nine-year incidence and risk factors for age-related macular degeneration in a defined Japanese population the Hisayama study. Ophthalmology 2009; 116: 2135-2140.
28. Brown GC, Brown MM, Sharma S, et al: The burden of age-related macular degeneration: a value-based medicine analysis. Trans Am Ophthalmol Soc 2005; 103: 173-184; discussion 184-186.
29. Brown MM, Brown GC, Stein JD, Roth Z, Campanella J, Beauchamp GR: Agerelated macular degeneration: economic burden and value-based medicine analysis. Can J Ophthalmol 2005; 40: 277-287.
30. Augustin A, Sahel JA, Bandello F, et al: Anxiety and depression prevalence rates in age-related macular degeneration. Invest Ophthalmol Vis Sci 2007; 48: 1498-1503.
31. Brody BL, Gamst AC, Williams RA, et al: Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. Ophthalmology 2001; 108: 1893-1900; discussion 1900-1901.
32. Berman K, Brodaty H: Psychosocial effects of age-related macular degeneration. Int Psychogeriatr 2006; 18: 415-428.
33. Thornton J, Edwards R, Mitchell P, Harrison RA, Buchan I, Kelly SP: Smoking and age-related macular degeneration: a review of association. Eye 2005; 19: 935-944.
34. Hageman GS, Anderson DH, Johnson LV, et al: A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA 2005; 102: 7227-7232.
35. Edwards AO, Ritter R 3rd, Abel KJ, Manning A, Panhuysen C, Farrer LA: Complement factor H polymorphism and age-related macular degeneration. Science 2005; 308: 421-424.
36. Klein RJ, Zeiss C, Chew EY, et al: Complement factor H polymorphism in agerelated macular degeneration. Science 2005; 308: 385-389.
37. Gold B, Merriam JE, Zernant J, et al: Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet 2006; 38: 458-462.
38. Kanda A, Chen W, Othman M, et al: A variant of mitochondrial protein LOC387715/ARMS2, not HTRA1, is strongly associated with age-related macular degeneration. Proc Natl Acad Sci USA 2007; 104: 16227-16232.
39. Dewan A, Liu M, Hartman S, et al: HTRA1 promoter polymorphism in wet age-related macular degeneration. Science 2006; 314: 989-992.
40. Yang Z, Camp NJ, Sun H, et al: A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration. Science 2006; 314: 992-993.
41. Jones MM, Manwaring N, Wang JJ, Rochtchina E, Mitchell P, Sue CM: Mitochondrial DNA haplogroups and agerelated maculopathy. Arch Ophthalmol 2007; 125: 1235-1240.
42. Davis MD, Gangnon RE, Lee LY, et al: The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS Report No. 17. Arch Ophthalmol 2005; 123: 1484-1498.
43. Bressler SB, Maguire MG, Bressler NM, Fine SL: Relationship of drusen and abnormalities of the retinal pigment epithelium to the prognosis of neovascular macular degeneration. The Macular Photocoagulation Study Group. Arch Ophthalmol 1990; 108: 1442-1447.
44. Nozaki M, Raisler BJ, Sakurai E, et al: Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci USA 2006; 103: 2328-2333.
45. Sunness JS, Gonzalez-Baron J, Bressler NM, Hawkins B, Applegate CA: The development of choroidal neovascularization in eyes with the geographic atrophy form of age-related macular degeneration. Ophthalmology 1999; 106: 910-919.
46. Green WR, Enger C: Age-related macular degeneration histopathologic studies. The 1992 Lorenz E. Zimmerman Lecture. Ophthalmology 1993; 100: 1519-1535.
47. Biarnes M, Mones J, Alonso J, Arias L: Update on geographic atrophy in agerelated macular degeneration. Optom Vis Sci 2011; 88: 881-889.
48. Sunness JS: The natural history of geographic atrophy, the advanced atrophic form of age-related macular degeneration. Mol Vis 1999; 5:25.
49. Sunness JS, Gonzalez-Baron J, Applegate CA, et al: Enlargement of atrophy and visual acuity loss in the geographic atrophy form of age-related macular degeneration. Ophthalmology 1999; 106: 1768-1779.
50. Sunness JS, Margalit E, Srikumaran D, et al: The long-term natural history of geographic atrophy from age-related macular degeneration: enlargement of atrophy and implications for interventional clinical trials. Ophthalmology 2007; 114: 271-277.
51. Curcio CA, Sloan KR, Kalina RE, Hendrickson AE: Human photoreceptor topography. J Comp Neurol 1990; 292: 497-523.
52. Sarks S: Ageing and degeneration in the macular region: a clinico-pathological study. Br J Ophthalmol 1976; 60: 324-341.
53. Sarks JP, Sarks SH, Killingsworth MC: Morphology of early choroidal neovascularisation in age-related macular degeneration: correlation with activity. Eye 1997; 11: 515-522.
54. Sarks JP, Sarks SH, Killingsworth MC: Evolution of soft drusen in age-related macular degeneration. Eye 1994; 8: 269-283.
55. Sarks S, Cherepanoff S, Killingsworth M, Sarks J: Relationship of Basal laminar deposit and membranous debris to the clinical presentation of early age-related macular degeneration. Invest Ophthalmol Vis Sci 2007; 48: 968-977.
56. Sarks SH: Drusen patterns predisposing to geographic atrophy of the retinal pigment epithelium. Aust J Ophthalmol 1982; 10: 91-97.
57. van der Schaft TL, Mooy C, de Bruijn WC, Oron FG, Mulder PG, de Jong PT: Histologic features of the early stages of age-related macular degeneration. Ophthalmology 1992; 99: 278-286.
58. Panda-Jonas S, Jonas JB, Jakobczyk-Zmija M: Retinal pigment epithelial cell count, distribution, and correlations in normal human eyes. Am J Ophthalmol 1996; 121: 181-189.
59. Gullapalli VK, Sugino IK, Van Patten Y, Shah S, Zarbin MA: Impaired RPE survival on aged submacular human Bruch's membrane. Exp Eye Res 2005; 80: 235-248.
60. Curcio CA, Millican CL: Basal linear deposit and large drusen are specific for early age-related maculopathy. Arch Ophthalmol 1999; 117: 329-339.
61. Bressler NM, Silva JC, Bressler SB, Fine SL, Green WR: Clinicopathologic correlation of drusen and retinal pigment epithelial abnormalities in age-related macular degeneration. Retina 1994; 14: 130-142.
62. Russell SR, Mullins RF, Schneider BL, Hageman GS: Location, substructure, and composition of basal laminar drusen compared with drusen associated with aging and age-related macular degeneration. Am J Ophthalmol 2000; 129: 205-214.
63. Sarks JP, Sarks SH, Killingsworth MC: Evolution of geographic atrophy of the retinal pigment epithelium. Eye 1988; 2: 552-577.
64. Mullins RF, Russell SR, Anderson DH, Hageman GS: Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J 2000; 14: 835-846.
65. Anderson DH, Mullins RF, Hageman GS, Johnson LV: A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol 2002; 134: 411-431.
66. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF: An integrated hypothesis that considers drusen as biomarkers of immunemediated processes at the RPE-Bruch's membrane interface in aging and agerelated macular degeneration. Prog Retin Eye Res 2001; 20: 705-732.
67. Crabb JW, Miyagi M, Gu X, et al: Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc Natl Acad Sci USA 2002; 99: 14682-14687.
68. Pauleikhoff D, Harper CA, Marshall J, Bird AC: Aging changes in Bruch's membrane. A histochemical and morphologic study. Ophthalmology 1990; 97: 171-178.
69. Sarks SH, Sarks JP, Killingsworth MC: Basal laminar deposit, membranous debris and drusen; in Zingirian M, Piccolino F (eds): Retinal Pigment Epithelium. Milan, Kugler and Ghedini, 1988, pp 187-190.
70. Arnold JJ, Sarks SH, Killingsworth MC, Sarks JP: Reticular pseudodrusen. A risk factor in age-related maculopathy. Retina 1995; 15: 183-191.
71. Zweifel SA, Spaide RF, Curcio CA, Malek G, Imamura Y: Reticular pseudodrusen are subretinal drusenoid deposits. Ophthalmology 2010; 117:303-312. e301.
72. Dunaief JL, Dentchev T, Ying GS, Milam AH: The role of apoptosis in age-related macular degeneration. Arch Ophthalmol 2002; 120: 1435-1442.
73. Curcio CA, Medeiros NE, Millican CL: Photoreceptor loss in age-related macular degeneration. Invest Ophthalmol Vis Sci 1996; 37: 1236-1249.
74. McLeod DS, Grebe R, Bhutto I, Merges C, Baba T, Lutty GA: Relationship between RPE and choriocapillaris in agerelated macular degeneration. Invest Ophthalmol Vis Sci 2009; 50: 4982-4991.
75. Bhutto I, Lutty G: Understanding agerelated macular degeneration (AMD): relationships between the photoreceptor/ retinal pigment epithelium/Bruch's membrane/choriocapillaris complex. Mol Aspects Med 2012; 33: 295-317.
76. Moore DJ, Hussain AA, Marshall J: Agerelated variation in the hydraulic conductivity of Bruch's membrane. Invest Ophthalmol Vis Sci 1995; 36: 1290-1297.
77. Starita C, Hussain AA, Pagliarini S, Marshall J: Hydrodynamics of ageing Bruch's membrane: implications for macular disease. Exp Eye Res 1996; 62: 565-572.
78. Starita C, Hussain AA, Patmore A, Marshall J: Localization of the site of major resistance to fluid transport in Bruch's membrane. Invest Ophthalmol Vis Sci 1997; 38: 762-767.
79. Curcio CA, Millican CL, Bailey T, Kruth HS: Accumulation of cholesterol with age in human Bruch's membrane. Invest Ophthalmol Vis Sci 2001; 42: 265-274.
80. Huang JD, Presley JB, Chimento MF, Curcio CA, Johnson M: Age-related changes in human macular Bruch's membrane as seen by quick-freeze/deep-etch. Exp Eye Res 2007; 85: 202-218.
81. Ruberti JW, Curcio CA, Millican CL, Menco BP, Huang JD, Johnson M: Quick-freeze/deep-etch visualization of age-related lipid accumulation in Bruch's membrane. Invest Ophthalmol Vis Sci 2003; 44: 1753-1759.
82. Li CM, Chung BH, Presley JB, et al: Lipoprotein-like particles and cholesteryl esters in human Bruch's membrane: initial characterization. Invest Ophthalmol Vis Sci 2005; 46: 2576-2586.
83. Pauleikhoff D, Loffert D, Spital G, et al: Pigment epithelial detachment in the elderly. Clinical differentiation, natural course and pathogenetic implications. Graefes Arch Clin Exp Ophthalmol 2002; 240: 533-538.
84. Macular Photocoagulation Study Group: Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Arch Ophthalmol 1997; 115: 741-747.
85. Bressler SB SJ, Bressler NM, Alexander J, Green WR: Clinicopathologic correlation of occult choroidal neovascularization in age-related macular degeneration. Arch Ophthalmol 1992; 110: 827-832.
86. Grossniklaus HE, Gass JD: Clinicopathologic correlations of surgically excised type 1 and type 2 submacular choroidal neovascular membranes. Am J Ophthalmol 1998; 126: 59-69.
87. Gass J: Biomicroscopic and histopathologic considerations regarding the feasibility of surgical excision of subfoveal neovascular membranes. Am J Ophthalmol 1994; 118: 285-298.
88. Lopez PF, Green WR: Peripapillary subretinal neovascularization. A review. Retina 1992; 12: 147-171.
89. Zarbin MA, Rosenfeld PJ: Pathwaybased therapies for age-related macular degeneration: an integrated survey of emerging treatment alternatives. Retina 2010; 30: 1350-1367.
90. Zarbin MA, Rosenfeld PJ: Review of emerging treatments of age-related macular degeneration; in Stratton RD, Hauswirth WW, Gardner TW (eds): Oxidative Stress in Applied Basic Research and Clinical Practice; Studies in Retinal and Choroidal Disorders. New York, Humana Press, 2012, pp 1-46.
91. Cano M, Thimmalappula R, Fujihara M, et al: Cigarette smoking, oxidative stress, the anti-oxidant response through Nrf2 signaling, and age-related macular degeneration. Vision Res 2010; 50: 652-664.
92. Canter JA, Olson LM, Spencer K, et al: Mitochondrial DNA polymorphism A4917G is independently associated with age-related macular degeneration. PLoS One 2008; 3:e2091.
93. Kimura K, Isashiki Y, Sonoda S, Kakiuchi-Matsumoto T, Ohba N: Genetic association of manganese superoxide dismutase with exudative age-related macular degeneration. Am J Ophthalmol 2000; 130: 769-773.
94. Jakobsdottir J, Conley YP, Weeks DE, Mah TS, Ferrell RE, Gorin MB: Susceptibility genes for age-related maculopathy on chromosome 10q26. Am J Hum Genet 2005; 77: 389-407.
95. Fritsche LG, Loenhardt T, Janssen A, et al: Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA. Nat Genet 2008; 40: 892-896.
96. Xu H, Chen M, Forrester JV: Para-inflammation in the aging retina. Prog Retin Eye Res 2009; 28: 348-368.
97. Gehrs KM, Jackson JR, Brown EN, Allikmets R, Hageman GS: Complement, age-related macular degeneration and a vision of the future. Arch Ophthalmol 2010; 128: 349-358.
98. Abdelsalam A, Del Priore L, Zarbin MA: Drusen in age-related macular degeneration: pathogenesis, natural course, and laser photocoagulationinduced regression. Surv Ophthalmol 1999; 44: 1-29.
99. Haines JL, Hauser MA, Schmidt S, et al: Complement factor H variant increases the risk of age-related macular degeneration. Science 2005; 308: 419-421.
100. Spencer KL, Hauser MA, Olson LM, et al: Protective effect of complement factor B and complement component 2 variants in age-related macular degeneration. Hum Mol Genet 2007; 16: 1986-1992.
101. Maller JB, Fagerness JA, Reynolds RC, Neale BM, Daly MJ, Seddon JM: Variation in complement factor 3 is associated with risk of age-related macular degeneration. Nat Genet 2007; 39: 1200-1201.
102. Yates JR, Sepp T, Matharu BK, et al: Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med 2007; 357: 553-561.
103. Zhu D, Deng X, Xu J, Hinton DR: What determines the switch between atrophic and neovascular forms of age related macular degeneration? - the role of BMP4 induced senescence. Aging (Albany NY) 2009; 1: 740-745.
104. Zhu D, Wu J, Spee C, Ryan SJ, Hinton DR: BMP4 mediates oxidative stressinduced retinal pigment epithelial cell senescence and is overexpressed in age-related macular degeneration. J Biol Chem 2009; 284: 9529-9539.
105. Yang Z, Stratton C, Francis PJ, et al: Toll-like receptor 3 and geographic atrophy in age-related macular degeneration. N Engl J Med 2008; 359: 1456-1463.
106. Age-Related Eye Disease Study Research Group: A randomized, placebocontrolled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report No. 8. Arch Ophthalmol 2001; 119: 1417-1436.
107. Age-Related Eye Disease Study 2 Research Group: Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 2013; 309: 2005-2015.
108. Lu M, Adamis AP: Molecular biology of choroidal neovascularization. Ophthalmol Clin North Am 2006; 19: 323-334.
109. Ferrara N, Mass RD, Campa C, Kim R: Targeting VEGF-A to treat cancer and age-related macular degeneration. Annu Rev Med 2007; 58: 491-504.
110. Rosenfeld PJ, Brown DM, Heier JS, et al: Ranibizumab for neovascular agerelated macular degeneration. N Engl J Med 2006; 355: 1419-1431.
111. Brown DM, Kaiser PK, Michels M, et al: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444.
112. Heier JS, Brown DM, Chong V, et al: Intravitreal aflibercept (VEGF trapeye) in wet age-related macular degeneration. Ophthalmology 2012; 119: 2537-2548.
113. Bloch SB, Larsen M, Munch IC: Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol 2012; 153: 209-213.
114. Claessen H, Genz J, Bertram B, et al: Evidence for a considerable decrease in total and cause-specific incidences of blindness in Germany. Eur J Epidemiol 2012; 27: 519-524.
115. Campbell JP, Bressler SB, Bressler NM: Impact of availability of anti-vascular endothelial growth factor therapy on visual impairment and blindness due to neovascular age-related macular degeneration. Arch Ophthalmol 2012; 130: 794-795.
116. Bressler NM, Doan QV, Varma R, et al: Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-Hispanic white population in the United States with age-related macular degeneration. Arch Ophthalmol 2011; 129: 709-717.
117. Kubota R, Boman NL, David R, Mallikaarjun S, Patil S, Birch D: Safety and effect on rod function of acu-4429, a novel small-molecule visual cycle modulator. Retina 2012; 32: 183-188.
118. Mata NL, Lichter JB, Vogel R, Han Y, Bui TV, Singerman LJ: Investigation of oral fenretinide for treatment of geographic atrophy in age-related macular degeneration. Retina 2013; 33: 498-507.
119. Garcia-Filho CA, Yehoshua Z, Gregori G, et al: Change in drusen volume as a novel clinical trial endpoint for the study of complement inhibition in agerelated macular degeneration. Ophthalmic Surg Lasers Imaging Retina 2014; 45: 18-31.
120. Zhang K, Hopkins JJ, Heier JS, et al: Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc Natl Acad Sci USA 2011; 108: 6241-6245.
121. Schwartz SD, Hubschman JP, Heilwell G, et al: Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet 2012; 379: 713-720.
122. Jin GF, Hurst JS, Godley BF: Rod outer segments mediate mitochondrial DNA damage and apoptosis in human retinal pigment epithelium. Curr Eye Res 2001; 23: 11-19.
123. Jarrett SG, Lin H, Godley BF, Boulton ME: Mitochondrial DNA damage and its potential role in retinal degeneration. Prog Retin Eye Res 2008; 27: 596-607.
124. Liang FQ, Godley BF: Oxidative stressinduced mitochondrial DNA damage in human retinal pigment epithelial cells: a possible mechanism for RPE aging and age-related macular degeneration. Exp Eye Res 2003; 76: 397-403.
125. Feher J, Kovacs I, Artico M, Cavallotti C, Papale A, Balacco Gabrieli C: Mitochondrial alterations of retinal pigment epithelium in age-related macular degeneration. Neurobiol Aging 2006; 27: 983-993.
126. Vives-Bauza C, Anand M, Shirazi AK, et al: The age lipid A2E and mitochondrial dysfunction synergistically impair phagocytosis by retinal pigment epithelial cells. J Biol Chem 2008; 283: 24770-24780.
127. Berg JM, Tymoczko JL, Stryer L: Biochemistry, ed 6. New York, WH Freeman, 2007.
128. Weber G: Fluorescence of riboflavin and flavin-adenine dinucleotide. Biochem J 1950; 47: 114-121.
129. Reinert KC, Dunbar RL, Gao W, Chen G, Ebner TJ: Flavoprotein autofluorescence imaging of neuronal activation in the cerebellar cortex in vivo. J Neurophysiol 2004; 92: 199-211.
130. Elner SG, Elner VM, Field MG, Park S, Heckenlively JR, Petty HR: Retinal flavoprotein autofluorescence as a measure of retinal health. Trans Am Ophthalmol Soc 2008; 106: 215-222; discussion 222-224.
131. Kennedy CJ, Rakoczy PE, Constable IJ: Lipofuscin of the retinal pigment epithelium: a review. Eye 1995; 9: 763-771.
132. Sparrow JR, Fishkin N, Zhou J, et al: A2E, a byproduct of the visual cycle. Vision Res 2003; 43: 2983-2990.
133. Holz FG, Bindewald-Wittich A, Fleckenstein M, Dreyhaupt J, Scholl HP, Schmitz-Valckenberg S: Progression of geographic atrophy and impact of fundus autofluorescence patterns in agerelated macular degeneration. Am J Ophthalmol 2007; 143: 463-472.
134. Delori FC, Dorey CK, Staurenghi G, Arend O, Goger DG, Weiter JJ: In vivo fluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics. Invest Ophthalmol Vis Sci 1995; 36: 718-729.
135. Rossi EA, Rangel-Fonseca P, Parkins K, et al: In vivo imaging of retinal pigment epithelium cells in age related macular degeneration. Biomed Opt Express 2013; 4: 2527-2539.
136. Radu RA, Han Y, Bui TV, et al: Reductions in serum vitamin A arrest accumulation of toxic retinal fluorophores: a potential therapy for treatment of lipofuscin-based retinal diseases. Invest Ophthalmol Vis Sci 2005; 46: 4393-4401.
137. Rudolf M, Vogt SD, Curcio CA, et al: Histologic basis of variations in retinal pigment epithelium autofluorescence in eyes with geographic atrophy. Ophthalmology 2013; 120: 821-828.
138. Spaide RF, Curcio CA: Drusen characterization with multimodal imaging. Retina 2010; 30: 1441-1454.
139. Weinberger AW, Lappas A, Kirschkamp T, et al: Fundus near infrared fluorescence correlates with fundus near infrared reflectance. Invest Ophthalmol Vis Sci 2006; 47: 3098-3108.
140. Schmitz-Valckenberg S, Lara D, Nizari S, et al: Localisation and significance of in vivo near-infrared autofluorescent signal in retinal imaging. Br J Ophthalmol 2011; 95: 1134-1139.
141. Elsner AE, Burns SA, Weiter JJ, Delori FC: Infrared imaging of sub-retinal structures in the human ocular fundus. Vision Res 1996; 36: 191-205.
142. Piccolino FC, Borgia L, Zinicola E, Iester M, Torrielli S: Pre-injection fluorescence in indocyanine green angiography. Ophthalmology 1996; 103: 1837-1845.
143. Huang D, Swanson EA, Lin CP, et al: Optical coherence tomography. Science 1991; 254: 1178-1181.
144. Costa RA, Skaf M, Melo LA Jr, et al: Retinal assessment using optical coherence tomography. Prog Retin Eye Res 2006; 25: 325-353.
145. Potsaid B, Baumann B, Huang D, et al: Ultrahigh speed 1050nm swept source/ Fourier domain OCT retinal and anterior segment imaging at 100,000 to 400,000 axial scans per second. Opt Express 2010; 18: 20029-20048.
146. Spaide RF, Koizumi H, Pozzoni MC: Enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophthalmol 2008; 146: 496-500.
147. Imamura Y, Fujiwara T, Margolis R, Spaide RF: Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina 2009; 29: 1469-1473.
148. Kim DY, Fingler J, Zawadzki RJ, et al: Optical imaging of the chorioretinal vasculature in the living human eye. Proc Natl Acad Sci USA 2013; 110: 14354-14359.
149. Schwartz DM, Fingler J, Kim DY, et al: Phase-variance optical coherence tomography. Ophthalmology 2014; 121: 180-187.
150. Zotter S, Pircher M, Torzicky T, et al: Visualization of microvasculature by dual-beam phase-resolved Doppler optical coherence tomography. Opt Express 2011; 19: 1217-1227.
151. Makita S, Jaillon F, Yamanari M, Miura M, Yasuno Y: Comprehensive in vivo micro-vascular imaging of the human eye by dual-beam-scan Doppler optical coherence angiography. Opt Express 2011; 19: 1271-1283.
152. Braaf B, Vermeer KA, Vienola KV, de Boer JF: Angiography of the retina and the choroid with phase-resolved OCT using interval-optimized backstitched B-scans. Opt Express 2012; 20: 20516-20534.
153. Grulkowski I, Gorczynska I, Szkulmowski M, et al: Scanning protocols dedicated to smart velocity ranging in spectral OCT. Opt Express 2009; 17: 23736-23754.
154. Liang J, Williams DR, Miller DT: Supernormal vision and high-resolution retinal imaging through adaptive optics. J Opt Soc Am A Opt Image Sci Vis 1997; 14: 2884-2892.
155. Roorda A, Romero-Borja F, Donnelly WI II, Queener H, Hebert T, Campbell M: Adaptive optics scanning laser ophthalmoscopy. Opt Express 2002; 10: 405-412.
156. Talcott KE, Ratnam K, Sundquist SM, et al: Longitudinal study of cone photoreceptors during retinal degeneration and in response to ciliary neurotrophic factor treatment. Invest Ophthalmol Vis Sci 2011; 52: 2219-2226.
157. Zhang Y, Poonja S, Roorda A: MEMSbased adaptive optics scanning laser ophthalmoscopy. Optics Lett 2006; 31: 1268-1270.
158. Fazelat A, Desai M, Nandakumar N, Lowry NC, Mangoubi R, Lashkari K: Enhanced, near-infrared fundus reflectance for qualitative and quantitative analysis of subretinal lesions. Exp Eye Res 2012; 96: 171-177.
159. Patton N, Aslam TM, MacGillivray T, et al: Retinal image analysis: concepts, applications and potential. Prog Retin Eye Res 2006; 25: 99-127.
160. Karwatowski WS, Jeffries TE, Duance VC, Albon J, Bailey AJ, Easty DL: Preparation of Bruch's membrane and analysis of the age-related changes in the structural collagens. Br J Ophthalmol 1995; 79: 944-952.
161. Haimovici R, Gantz DL, Rumelt S, Freddo TF, Small DM: The lipid composition of drusen, Bruch's membrane, and sclera by hot stage polarizing light microscopy. Invest Ophthalmol Vis Sci 2001; 42: 1592-1599.
162. Marshall J, Hussain AA, Starita C, Moore DJ, Patmore AL: Aging and Bruch's membrane; in Marmor MF, Wolfensberger TJ (eds): The Retinal Pigment Epithelium. New York, Oxford University Press, 1998, pp 669-692.
163. Curcio CA, Johnson M, Huang JD, Rudolf M: Apolipoprotein B-containing lipoproteins in retinal aging and agerelated macular degeneration. J Lipid Res 2010; 51: 451-467.
164. Handa JT, Verzijl N, Matsunaga H, et al: Increase in the advanced glycation end product pentosidine in Bruch's membrane with age. Invest Ophthalmol Vis Sci 1999; 40: 775-779.
165. Margolis R, Spaide RF: A pilot study of enhanced depth imaging optical coherence tomography of the choroid in normal eyes. Am J Ophthalmol 2009; 147: 811-815.
166. Barteselli G, Chhablani J, El-Emam S, et al: Choroidal volume variations with age, axial length, and sex in healthy subjects: a three-dimensional analysis. Ophthalmology 2012; 119: 2572-2578.
167. Manjunath V, Goren J, Fujimoto JG, Duker JS: Analysis of choroidal thickness in age-related macular degeneration using spectral-domain optical coherence tomography. Am J Ophthalmol 2011; 152: 663-668.
168. Ko A, Cao S, Pakzad-Vaezi K, et al: Optical coherence tomography-based correlation between choroidal thickness and drusen load in dry age-related macular degeneration. Retina 2013; 33: 1005-1010.
169. Lee JY, Lee DH, Yoon YH: Correlation between subfoveal choroidal thickness and the severity or progression of nonexudative age-related macular degeneration. Invest Ophthalmol Vis Sci 2013; 54: 7812-7818.
170. Pauleikhoff D, Zuels S, Sheraidah GS, Marshall J, Wessing A, Bird AC: Correlation between biochemical composition and fluorescein binding of deposits in Bruch's membrane. Ophthalmology 1992; 99: 1548-1553.
171. Leng T, Rosenfeld PJ, Gregori G, Puliafito CA, Punjabi OS: Spectral domain optical coherence tomography characteristics of cuticular drusen. Retina 2009; 29: 988-993.
172. Forte R, Querques G, Querques L, Massamba N, Le Tien V, Souied EH: Multimodal imaging of dry age-related macular degeneration. Acta Ophthalmol 2012; 90:e281-e287.
173. Querques G, Georges A, Ben Moussa N, Sterkers M, Souied E: Appearance of regressing drusen on optical coherence tomography in age-related macular degeneration. Ophthalmology 2014; 121: 173-179.
174. Spaide RF: Enhanced depth imaging optical coherence tomography of retinal pigment epithelial detachment in age-related macular degeneration. Am J Ophthalmol 2009; 147: 644-652.
175. Cahill MT, Mruthyunjaya P, Bowes Rickman C, Toth CA: Recurrence of retinal pigment epithelial changes after macular translocation with 360 degrees peripheral retinectomy for geographic atrophy. Arch Ophthalmol 2005; 123: 935-938.
176. Johnson PT, Brown MN, Pulliam BC, Anderson DH, Johnson LV: Synaptic pathology, altered gene expression, and degeneration in photoreceptors impacted by drusen. Invest Ophthalmol Vis Sci 2005; 46: 4788-4795.
177. Schuman SG, Koreishi AF, Farsiu S, Jung SH, Izatt JA, Toth CA: Photoreceptor layer thinning over drusen in eyes with age-related macular degeneration imaged in vivo with spectraldomain optical coherence tomography. Ophthalmology 2009; 116:488-496. e482.
178. Godara P, Siebe C, Rha J, Michaelides M, Carroll J: Assessing the photoreceptor mosaic over drusen using adaptive optics and SD-OCT. Ophthalmic Surg Lasers Imaging 2010; 41(suppl):S104-S108.
179. Boretsky A, Khan F, Burnett G, et al: In vivo imaging of photoreceptor disruption associated with age-related macular degeneration: a pilot study. Lasers Surg Med 2012; 44: 603-610.
180. Zayit-Soudry S, Duncan JL, Syed R, Menghini M, Roorda AJ: Cone structure imaged with adaptive optics scanning laser ophthalmoscopy in eyes with nonneovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2013; 54: 7498-7509.
181. Brar M, Kozak I, Cheng L, et al: Correlation between spectral-domain optical coherence tomography and fundus autofluorescence at the margins of geographic atrophy. Am J Ophthalmol 2009; 148: 439-444.
182. Roorda A, Williams DR: Optical fiber properties of individual human cones. J Vis 2002; 2: 404-412.
183. Hartmann KI, Gomez ML, Bartsch DU, Schuster AK, Freeman WR: Effect of change in drusen evolution on photoreceptor inner segment/outer segment junction. Retina 2012; 32: 1492-1499.
184. Fleckenstein M, Charbel Issa P, Helb HM, et al: High-resolution spectral domain-OCT imaging in geographic atrophy associated with age-related macular degeneration. Invest Ophthalmol Vis Sci 2008; 49: 4137-4144.
185. Bearelly S, Chau FY, Koreishi A, Stinnett SS, Izatt JA, Toth CA: Spectral domain optical coherence tomography imaging of geographic atrophy margins. Ophthalmology 2009; 116: 1762-1769.
186. Nunes RP, Gregori G, Yehoshua Z, et al: Predicting the progression of geographic atrophy in age-related macular degeneration with SD-OCT en face imaging of the outer retina. Ophthalmic Surg Lasers Imaging Retina 2013; 44: 344-359.
187. von Ruckmann A, Fitzke FW, Bird AC: Fundus autofluorescence in age-related macular disease imaged with a laser scanning ophthalmoscope. Invest Ophthalmol Vis Sci 1997; 38: 478-486.
188. Schmitz-Valckenberg S, Bindewald-Wittich A, Dolar-Szczasny J, et al: Correlation between the area of increased autofluorescence surrounding geographic atrophy and disease progression in patients with AMD. Invest Ophthalmol Vis Sci 2006; 47: 2648-2654.
189. Sayegh RG, Simader C, Scheschy U, et al: A systematic comparison of spectral-domain optical coherence tomography and fundus autofluorescence in patients with geographic atrophy. Ophthalmology 2011; 118: 1844-1851.
190. Kaneko H, Dridi S, Tarallo V, et al: DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. Nature 2011; 471: 325-330.
191. Midena E, Vujosevic S, Convento E, Manfre A, Cavarzeran F, Pilotto E: Microperimetry and fundus autofluorescence in patients with early age-related macular degeneration. Br J Ophthalmol 2007; 91: 1499-1503.
192. Querques L, Querques G, Forte R, Souied EH: Microperimetric correlations of autofluorescence and optical coherence tomography imaging in dry agerelated macular degeneration. Am J Ophthalmol 2012; 153: 1110-1115.
193. Kellner U, Kellner S, Weinitz S: Fundus autofluorescence (488 nm) and near-infrared autofluorescence (787 nm) visualize different retinal pigment epithelium alterations in patients with age-related macular degeneration. Retina 2010; 30: 6-15.
194. Landa G, Su E, Garcia PM, Seiple WH, Rosen RB: Inner segment-outer segment junctional layer integrity and corresponding retinal sensitivity in dry and wet forms of age-related macular degeneration. Retina 2011; 31: 364-370.
195. Farsiu S, Chiu SJ, O'Connell RV, et al: Quantitative classification of eyes with and without intermediate age-related macular degeneration using optical coherence tomography. Ophthalmology 2014; 121: 162-172.
196. Yehoshua Z, Rosenfeld PJ, Gregori G, et al: Progression of geographic atrophy in age-related macular degeneration imaged with spectral domain optical coherence tomography. Ophthalmology 2011; 118: 679-686.
197. Yehoshua Z, Wang F, Rosenfeld PJ, Penha FM, Feuer WJ, Gregori G: Natural history of drusen morphology in age-related macular degeneration using spectral domain optical coherence tomography. Ophthalmology 2011; 118: 2434-2441.
198. Gregori G, Wang F, Rosenfeld PJ, et al: Spectral domain optical coherence tomography imaging of drusen in nonexudative age-related macular degeneration. Ophthalmology 2011; 118: 1373-1379.
199. Freeman SR, Kozak I, Cheng L, et al: Optical coherence tomography-raster scanning and manual segmentation in determining drusen volume in agerelated macular degeneration. Retina 2010; 30: 431-435.
200. Schmitz-Valckenberg S, Fleckenstein M, Gobel AP, Hohman TC, Holz FG: Optical coherence tomography and autofluorescence findings in areas with geographic atrophy due to age-related macular degeneration. Invest Ophthalmol Vis Sci 2011; 52: 1-6.
201. Sunness JS, Bressler NM, Tian Y, Alexander J, Applegate CA: Measuring geographic atrophy in advanced age-related macular degeneration. Invest Ophthalmol Vis Sci 1999; 40: 1761-1769.
202. Mauschitz MM, Fonseca S, Chang P, et al: Topography of geographic atrophy in age-related macular degeneration. Invest Ophthalmol Vis Sci 2012; 53: 4932-4939.
203. Schmitz-Valckenberg S, Fleckenstein M, Gobel AP, et al: Evaluation of autofluorescence imaging with the scanning laser ophthalmoscope and the fundus camera in age-related geographic atrophy. Am J Ophthalmol 2008; 146: 183-192.
204. Holz FG, Bellman C, Staudt S, Schutt F, Volcker HE: Fundus autofluorescence and development of geographic atrophy in age-related macular degeneration. Invest Ophthalmol Vis Sci 2001; 42: 1051-1056.
205. Khanifar AA, Lederer DE, Ghodasra JH, et al: Comparison of color fundus photographs and fundus autofluorescence images in measuring geographic atrophy area. Retina 2012; 32: 1884-1891.
206. Grunwald JE, Metelitsina TI, Dupont JC, Ying GS, Maguire MG: Reduced foveolar choroidal blood flow in eyes with increasing AMD severity. Invest Ophthalmol Vis Sci 2005; 46: 1033-1038.
207. Berenberg TL, Metelitsina TI, Madow B, et al: The association between drusen extent and foveolar choroidal blood flow in age-related macular degeneration. Retina 2012; 32: 25-31.